These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 18360588)

  • 1. Voriconazole in the management of nosocomial invasive fungal infections.
    Pemán J; Salavert M; Cantón E; Jarque I; Romá E; Zaragoza R; Viudes A; Gobernado M
    Ther Clin Risk Manag; 2006 Jun; 2(2):129-58. PubMed ID: 18360588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Voriconazole: therapeutic review of a new azole antifungal.
    Herbrecht R
    Expert Rev Anti Infect Ther; 2004 Aug; 2(4):485-97. PubMed ID: 15482215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Voriconazole: a new triazole antifungal agent.
    Johnson LB; Kauffman CA
    Clin Infect Dis; 2003 Mar; 36(5):630-7. PubMed ID: 12594645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Voriconazole.
    Jeu L; Piacenti FJ; Lyakhovetskiy AG; Fung HB
    Clin Ther; 2003 May; 25(5):1321-81. PubMed ID: 12867215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Voriconazole : a review of its use in the management of invasive fungal infections.
    Scott LJ; Simpson D
    Drugs; 2007; 67(2):269-98. PubMed ID: 17284090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Voriconazole: a broad spectrum triazole for the treatment of serious and invasive fungal infections.
    Maschmeyer G; Haas A
    Future Microbiol; 2006 Dec; 1(4):365-85. PubMed ID: 17661629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Voriconazole -- better chances for patients with invasive mycoses.
    Ghannoum MA; Kuhn DM
    Eur J Med Res; 2002 May; 7(5):242-56. PubMed ID: 12069915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Voriconazole: a broad-spectrum triazole for the treatment of invasive fungal infections.
    Cecil JA; Wenzel RP
    Expert Rev Hematol; 2009 Jun; 2(3):237-54. PubMed ID: 21082966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antifungal activity of the new azole UK-109, 496 (voriconazole).
    Kappe R
    Mycoses; 1999 Dec; 42 Suppl 2():83-86. PubMed ID: 29265604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of invasive fungal infections with voriconazole. Evaluation of experience with compassionate use of voriconazole in Spain].
    Díaz Pedroche C; Cisneros JM; Lumbreras C; Aguado JM;
    Rev Esp Quimioter; 2005 Jun; 18(2):149-58. PubMed ID: 16130037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [In vitro activity of voriconazole against yeast and algae isolates according to new resistance pattern cut-off points].
    Pemán J; Cantón E; Calabuig E; Bosch M; Valentí A; Viudes A; Gobernado M
    Rev Esp Quimioter; 2006 Mar; 19(1):21-33. PubMed ID: 16688288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of voriconazole against yeasts, moulds and dermatophytes in comparison with fluconazole, amphotericin B and griseofulvin.
    Wildfeuer A; Seidl HP; Paule I; Haberreiter A
    Arzneimittelforschung; 1997 Nov; 47(11):1257-63. PubMed ID: 9428984
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Pfaller MA; Huband MD; Flamm RK; Bien PA; Castanheira M
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changing epidemiology of rare mould infections: implications for therapy.
    Malani AN; Kauffman CA
    Drugs; 2007; 67(13):1803-12. PubMed ID: 17722951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance in human pathogenic yeasts and filamentous fungi: prevalence, underlying molecular mechanisms and link to the use of antifungals in humans and the environment.
    Jensen RH
    Dan Med J; 2016 Oct; 63(10):. PubMed ID: 27697142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic considerations in the treatment of invasive aspergillosis: a review of voriconazole pharmacoeconomic studies.
    Krueger KP; Nelson AC
    Clinicoecon Outcomes Res; 2009; 1():35-43. PubMed ID: 21935305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.
    Pfaller MA; Messer SA; Hollis RJ; Jones RN;
    Antimicrob Agents Chemother; 2002 Apr; 46(4):1032-7. PubMed ID: 11897586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Voriconazole for serious fungal infections.
    Gothard P; Rogers TR
    Int J Clin Pract; 2004 Jan; 58(1):74-80. PubMed ID: 14994974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antifungal activity of the new azole UK-109, 496 (voriconazole).
    Kappe R
    Mycoses; 1999; 42 Suppl 2():83-6. PubMed ID: 10865910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.